AntonioJimenoMD

Oncology • Aurora, CO

Associate Professor, Medicine, University of Colorado School of Medicine

Join to view full profile

Are you Dr. Jimeno?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 36 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
12605 E 16th Ave
Aurora, CO 80045
Phone+1 720-848-0000

Fax+1 720-848-0360

Summary

Dr. Antonio Jimeno, MD is an oncologist in Aurora, Colorado. He is currently licensed to practice medicine in Colorado. He is affiliated with University of Colorado Hospital and is an Associate Professor at University of Colorado School of Medicine.

Education & Training

Johns Hopkins UniversityFellowship, Medical Oncology, 2006
University of Valladolid Faculty of MedicineClass of 1999

Certifications & Licensure

CO State Medical License 2008 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors Start of enrollment: 2009 Jan 01
Completed
Phase 1
Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors Start of enrollment: 2010 Jul 01
Completed
Phase 1
Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer Start of enrollment: 2011 Apr 01
Completed
Phase 1
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer Start of enrollment: 2011 May 01
Completed
Phase 3
Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks Start of enrollment: 2011 Nov 01
Completed
Phase 1
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2012 Nov 12
Terminated
Phase 1, Phase 2
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies Start of enrollment: 2013 Oct 01
Completed
Phase 1
Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer Start of enrollment: 2014 Jan 01
Completed
Phase 1
Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors Start of enrollment: 2014 Jun 01
Terminated
Phase 1
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Start of enrollment: 2014 Sep 05
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Sacituzumab Govitecan in Patients With Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma: Results From the Phase 2 TROPiCS-03 Basket Study.
Loren Michel, Antonio Jimeno, Ammar Sukari, J Thaddeus Beck, Joanne Chiu
Clinical Cancer Research. 2024-12-12
Histone-methyltransferase KMT2D deficiency impairs the Fanconi anemia/BRCA pathway upon glycolytic inhibition in squamous cell carcinoma.
Wei Liu, Hongchao Cao, Jing Wang, Areeg Elmusrati, Bing Han
Nature Communications. 2024-08-08
Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+...
Alice N Weaver, Wade T Iams, Jong Chul Park, Monica Mita, Udo Holtick
Molecular Carcinogenesis. 2024-08-01

Press Mentions

Microfluidic Pinch Technology May Treat Head and Neck Cancer: ResearchMarch 12th, 2023
Health News | Microfluidic Squeezing Technology Can Treat Head, Neck Cancer: ResearchMarch 12th, 2023
Innovative Technology Again Promises Big PromisesMarch 4th, 2023
Join now to see all